At the LUGPA 2024 Annual Meeting, Jason Hafron, MD, Michigan Institute of Urology, shares his perspective on the evolving landscape of upper tract urothelial carcinoma (UTUC) management, highlighting key trends and advancements for 2025. Building on recent data from the OLYMPUS trial and real-world evidence, Dr. Hafron discusses the increasing adoption of mitomycin for chemoablation and as an adjuvant therapy, as well as the growing emphasis on kidney-sparing approaches for low-risk patients. ...
Upper Tract Urothelial Carcinoma
Advertisement
Latest News
Drs. Michael Whalen and Vincent Xu discuss potential alternative treatments for patients who are ineligible for chemotherapy.
Drs. Michael Whalen and Vincent Xu discuss their recent analysis of neoadjuvant chemotherapy utilization for UTUC.
Drs. Sundaram and Murray highlight the results of a study on robotic nephroureterectomy and bladder cuff excision for UTUC.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
NLR can be a prognostic predictor of clinicopathology in UTUC, aiding risk stratification and management.
A meta-analysis sought to determine the surgical and oncological outcomes of LNU and ONU in patients with UTUC.
For patients with UTUC, bladder cuff excision and radical nephroureterectomy is a longstanding treatment.
The study’s data set included abstracted clinical data with germline and tumor genomic data.
Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations.
Advertisement
Roundtable Discussions
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Urothelial Cancer Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Advertisement
Section Editor
Katie S. Murray, DO, MSUrologic Oncologist | NYU Langone Urology and Bellevue Hospital
Advertisement
Get the latest UTUC research straight to your inbox.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.